NurseBeats
Breaking news and information from the CDC, FDA and nursing journals.
FDA Approves Drug for Heart Disorder Caused by Transthyretin-Mediated Amyloidosis
FDA approved Attruby (acoramidis) to treat adults with cardiomyopathy (disorder that affects heart muscle) of wild-type or variant (hereditary) transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.
Read MorePreventing Hypothermia in Newborns With Congenital Anomalies in the Delivery Room
The interventions significantly reduced the number of neonates admitted to the ICU with hypothermia. Implementation of thermoregulation bundles should apply to all neonates with congenital anomalies to decrease risks associated with hypothermia.
Read MoreCDC Issues Health Alert In Light of Disruptions in Availability of PD and IV Solutions from Baxter International Facility in North Carolina
The supply disruption may impact patient care and require adjustments to the clinical management of patients. Healthcare providers, pharmacists, healthcare facility administrators, and state, tribal, local, and territorial health departments, regardless of supply chain disruptions, should immediately assess their supply and develop plans and mitigation strategies to reduce the impact on patient care.
Read MoreTelehealth Privacy and Security Tips
Buzz, a HIPAA-complaint platform enables providers to conduct secure video conferences or calls with patients quickly, easily & seamlessly.
Read MoreA Simple Blood Test Warns of Possible Cardiometabolic Complications for Children With Obesity
Scientists from the University of Copenhagen have detected lipid biomarkers in children and teenagers with obesity that indicate an increased risk of developing type 2 diabetes, liver and heart disease as adults. A one-year lifestyle intervention lowered the levels of these lipid biomarkers, which demonstrates the importance of early intervention for children with obesity.
Read MoreFDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration
FDA approved FluMist for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age.
Read MoreThe Impact of Mandated Use Early Warning System Tools on the Development of Nurses' Higher-Order Thinking
EWSs can support and suppress nurses' higher-order thinking. EWS as a supportive factor reinforces the development of nurses' heuristics, the mental shortcuts experienced clinicians call on when interpreting their subjective clinical assessment of patients.
Read MoreEfficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia
In this phase 3, double-blind, randomized, placebo-controlled trial in 256 people with schizophrenia, xanomeline-trospium was associated with a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale total score compared with placebo. Xanomeline-trospium was generally well tolerated; the most common adverse events were primarily gastrointestinal effects, which were mild or moderate in intensity and generally transient in nature.
Read MoreStrategies to Improve Sleep Quality in Intensive Care Unit Patients
The most effective way to improve sleep for intensive care unit patients is to use a combination of pharmacologic and nonpharmacologic interventions. Among the latter, the use of earplugs and sleep masks is simplest.
Read MoreAn Investigation of Trachoma Vaccine Regimens by the Chlamydia Vaccine CTH522 Administered With Cationic Liposomes in Healthy Adults (CHLM-02)
CTH522, adjuvanted with CAF01 or CAF09b, is safe and immunogenic, with 85 µg CTH522-CAF01 inducing robust serum IgG binding titres. Intradermal vaccination conferred systemic IgG neutralisation breadth, and topical ocular administration increased ocular IgA formation. These findings indicate CTH522 vaccine regimens against ocular trachoma and urogenital chlamydia for testing in phase 2, clinical trials.
Read MoreDoes Mixing Activated Charcoal With Cola Improve Tolerability Without Affecting Pharmacokinetics?
In this small study, there was no difference in preference for activated charcoal alone or a cola-activated charcoal mixture across a range of palatability questions. On an individual level, some participants preferred the activated charcoal-cola mixture, and some preferred the activated charcoal alone.
Read More